Highlights

  • Amplia Therapeutics (ASX:ATX) reported a 36% confirmed response rate in ACCENT.
  • One ACCENT participant remained on study, while two completed 24 months.
  • September-quarter closing cash was AUD 20.8 million before October tax receipts.
  • Upcoming studies cover pancreatic, ovarian and lung cancer indications.

Amplia Therapeutics Limited is an Australian biotechnology company researching focal adhesion kinase inhibitors for cancer and fibrosis, with narmafotinib as its principal clinical candidate. Its ASX-listed shares were trading at AUD 0.084 on 13 November 2026, down 2.33% during the session under ticker ASX:ATX. October trial and quarterly reports describe continued pancreatic cancer observations, preparations for further studies and the company's development funding.

Cancer Research and Narmafotinib

Amplia (ASX:ATX) is investigating narmafotinib, also known as AMP945, as a treatment used with other cancer medicines rather than as an approved standalone product. It targets focal adhesion kinase (FAK), a protein involved in cellular signalling and fibrotic tumour environments. The research programme includes pancreatic cancer, ovarian cancer and a planned combination study in non-small cell lung cancer.

Its ACCENT study evaluates narmafotinib alongside gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic cancer. AMPLICITY has assessed narmafotinib with modified FOLFIRINOX chemotherapy. The programmes differ in their accompanying drugs and safety considerations, so outcomes should not be treated as interchangeable.

October Clinical Updates and Trial Pipeline

Amplia said in October 2026 that ACCENT had recorded a 36% confirmed overall response rate, rising to 42% when unconfirmed responses were included. The reported complete response rate was 7.8%, while median overall survival was 11.1 months. These results come from a clinical study and are not evidence of Marketing approval or guaranteed outcomes in larger trials.

According to the 22 October update, one ACCENT patient remained on study after about 19 months and two others had completed 24 months. In AMPLICITY, recruitment was stopped after three dose-limiting toxicities attributed to the chemotherapy regimen. The company reported one confirmed and one unconfirmed partial response, with one patient still participating.

Preparations were also advancing for ACCENT-Mini, which will examine different daily narmafotinib doses with chemotherapy. Three Australian sites had been selected and ethics approval was being sought. Amplia expects safety and pharmacokinetic data in late first-quarter or early second-quarter 2027 to inform discussions concerning a registrational trial. An ovarian cancer study named PRROSE had submitted its ethics application, while a collaboration with Eli Lilly addresses a proposed narmafotinib and olomorasib study in lung cancer.

Quarterly Cash Flow and Financial Context

Amplia (ASX:ATX) finished September 2026 with AUD 20.8 million in cash, compared with AUD 24.0 million at the end of June. Operating cash outflow was AUD 3.1 million during the September quarter, against AUD 3.9 million in the preceding quarter. The September outflow included about AUD 2.1 million for Research and Development and approximately AUD 1.2 million for staff, administration and corporate costs, partly offset by interest receipts.

The company received an AUD 4.8 million research-and-development tax incentive refund in October. Its reported pro forma September cash figure, after recognising that subsequent receipt, was AUD 25.6 million. These are differently dated measures and should not be combined as though both amounts were held at September-end.

Risks and What to Watch Next

Clinical responses in early or mid-stage studies may not persist in larger patient populations. Trial approvals, recruitment, dosing decisions, adverse events and access to additional funding remain relevant uncertainties. Results from different chemotherapy combinations also require separate interpretation.

Near-term monitoring points include ACCENT-Mini ethics clearance and commencement, PRROSE study start-up, the proposed lung cancer combination study and future financial reports. Management has indicated that ACCENT-Mini data should support a planned US regulatory protocol discussion in 2027.

Key Insights

Amplia (ASX:ATX) is moving from reported ACCENT observations towards several further trial programmes. Its September cash balance, October tax receipt and continuing research expenditure help frame the resources available. Clinical safety, trial initiation and the timing of subsequent data will remain the main measurable updates.